Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Pozycja w akcjach #2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Cena akcji
$79.61
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$6.21B
Zmiana (1 dzień)
1.30%
Zmiana (1 rok)
104.18%
Kraj
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)

Kategoria

Healthcare
Wskaźnik P/S dla Kiniksa Pharmaceuticals International, plc (KNSA)
Wskaźnik P/S na dzień October 2026 TTM: 7.32
Według najnowszych raportów finansowych i ceny akcji Kiniksa Pharmaceuticals International, plc, obecny wskaźnik P/S (TTM) wynosi 7.32. Na koniec 2023 wynosił 4.55.
Historia wskaźnika P/S dla Kiniksa Pharmaceuticals International, plc od 2016 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 7.32 119.03%
2024 3.34 -26.59%
2023 4.55 -3.68%
2022 4.72 -77.46%
2021 20.94 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów